Flash | Pfizer (PFE.N) 04 Aug 2026 07:44:05 ET │ 11 pages Initial thoughts on 2Q26; Broad product upside offsets COVID weakness; Revenue guidance raised CITI'S TAKE Pfizer reported 2Q26 revenues of $15.0B (+3% y/y, +$655M vs cons) and non-GAAP EPS of $0.77 (-1% y/y, +$0.09 vs cons). Eliquis led upside at $2.43B (+$357M), driven by U.S. pricing, channel mix and global demand. Ibrance was $1.06B (+$83M), while Vyndaqel reached $1.76B (+$60M) on diagnosis and market expansion, partly offset by U.S. net-price e ...